BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage

Kajal Biswas, Subha Philip, Aditya Yadav, Betty K. Martin, Sandra Burkett, Vaibhav Singh, Anav Babbar, Susan Lynn North, Suhwan Chang & Shyam K. Sharan

BRCA2 is essential for maintaining genomic integrity. BRCA2-deficient primary cells are either not viable or exhibit severe proliferation defects. Yet, BRCA2 deficiency contributes to tumorigenesis. It is believed that mutations in genes such as TRP53 allow BRCA2 heterozygous cells to overcome growth arrest when they undergo loss of heterozygosity. Here, we report the use of an insertional mutagenesis screen to identify a role for BRE (Brain and Reproductive organ Expressed, also known as BRCC45), known to be a part of the BRCA1-DNA damage sensing complex, in the survival of BRCA2-deficient mouse ES cells. Cell viability by BRE overexpression is mediated by deregulation of CDC25A phosphatase, a key cell cycle regulator and an oncogene. We show that BRE facilitates deubiquitylation of CDC25A by recruiting ubiquitin-specific-processing protease 7 (USP7) in the presence of DNA damage. Additionally, we uncovered the role of CDC25A in BRCA-mediated tumorigenesis, which can have implications in cancer treatment.

1 Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA. 2 Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA. 3Present address: Maxim Biomedical Inc., Rockville, MD 20850, USA. 4Present address: Department of Biomedical Sciences, Department of Physiology, University of Ulsan School of Medicine, Seoul 05505, South Korea. Correspondence and requests for materials should be addressed to S.K.S. (email: sharans@mail.nih.gov)
Inherited mutations in BRCA2 are not only associated with increased risk of breast and ovarian cancer but also prostate, pancreatic, and other cancers\textsuperscript{1-6}. BRCA2 is required for RAD51-mediated repair of DNA double strand breaks (DSB) by homologous recombination (HR) as well as for protecting stalled replication forks\textsuperscript{7-9}. BRCA2-deficient cells undergo tumorigenesis due to their unstable genome\textsuperscript{10}. Paradoxically, loss of BRCA2 in normal cells leads to cell cycle arrest and apoptosis due to the activation of the DNA damage response (DDR) rather than unrestrained proliferation, characteristic of cancer cells\textsuperscript{11,12}. It has been postulated that mutation in genes such as TRP53 contributes to the survival of BRCA2-deficient cells. In mice, the lethality of Brca2-null embryos can be partially rescued on a TRp53-deficient genetic background and significant enhancement of tumorigenesis was observed when Brca2 loss was combined with a Trp53 mutation in mice\textsuperscript{13,14}. Although mutations in TRP53 have been identified in tumors from BRCA2 mutation carriers\textsuperscript{15,16}, it is not inactivated in all BRCA2-deficient tumors, suggesting the existence of alternative routes to overcome growth arrest of BRCA2-deficient cells. The evidence for the existence of such BRCA2-cooperating genes to promote tumorigenesis is very limited. We have recently shown that Parp1 heterozygosity can contribute to the viability of Brca2-null cells as well as tumorigenesis in Brca2 mutant mice\textsuperscript{17}. In the current study, we have undertaken an insertional mutagenesis approach using Murine Stem Cell Virus (MSCV) to identify novel genes that can support the survival of BRCA2-deficient cells. Recently, we identified upregulation of Gipc3 to rescue the viability of Brca2-null ES cells using a similar approach\textsuperscript{18}.

Our MSCV-based genetic screen resulted in the identification of BRE that can support the viability and growth of Brca2-null cells by regulating cell cycle checkpoint protein CDC25A. BRE, an evolutionarily conserved stress-modulating gene, is upregulated in hepatocellular carcinoma and has been identified as a risk-modifier of BRCA1-associated ovarian cancer\textsuperscript{19,20}. BRE was found to be a part of the BRCA1-A and multiprotein BRISC complex (BRCC36 isopeptidase complex) that specifically cleaves K-63 polyubiquitins in various sub- strates\textsuperscript{21,22}. Interaction of BRE with MERIT40 is required to maintain the integrity of BRCA1-A complex\textsuperscript{23}. BRE and BRCC36 interaction is also important for E3 ligase activity of BRCA1-BARD1 heterodimer and K-63 deubiquitylase activity of BRCC36\textsuperscript{22,24}. BRE knockdown disrupts BRCA1 foci formation at DNA damage sites and thus plays an important role in DNA repair\textsuperscript{25,26}. It is known to interact with Fas and TNF-R1 and acts as a death receptor-associated anti-apoptotic protein\textsuperscript{26,27}. BRE-null mice are viable and fertile and exhibit no overt phenotype\textsuperscript{28}. However, fibroblasts derived from mutant mice show proliferation defect, premature senescence, and a defect in DSBR by HIR\textsuperscript{28}.

Here, we show that BRE regulates the levels of CDC25A in response to DNA damage by promoting its deubiquitylation via its interaction with ubiquitin-specific-processing protease 7 (USP7). The BRE–CDC25A–USP7 complex is a multiprotein complex that is distinct from the well-established BRE containing BRISC or BRCA1-A complex. We further show that this new function of BRE in CDC25A regulation plays an important role in the survival of BRCA1/2-deficient cells. Importantly, we found higher expression of CDC25A in BRCA1/2-deficient tumors in different breast cancer data sets. Furthermore, we confirmed a positive correlation between BRE and CDC25A levels in human breast tumors. Overall, we demonstrate that CDC25A is a critical factor in the survival and growth of BRCA1/2-deficient cells and BRE, an adapter protein, plays an important role in regulating the CDC25A protein levels by recruiting USP7.

**Results**

**Genetic screen to identify BRCA2 genetic interactors.** To identify the genes that may cooperate with Brca2 in the process of tumorigenesis by contributing to cell viability, we performed an MSCV-based insertional mutagenesis screen in mES cells. We hypothesized that any mutation due to the viral insertion that supports the viability of Brca2\textsuperscript{K0/K0} cells can be a potential genetic interactor. We used MSCV because its strong long terminal repeats (LTRs) are known to be active in several mammalian cell lines including ES cells and can induce the expression of neighboring genes\textsuperscript{18,19}. Viral insertion can also disrupt genes. We used the previously reported PL2F7 mES cells that have one conditional allele of Brca2 (CKO) and the other allele is functionally null (KO) to perform the mutagenesis screen\textsuperscript{6}. In these cells, CRE-mediated deletion of the conditional allele generates a functional HPRT minigene that allows selection of recombinant clones. Because BRCA2 is essential for cell viability, no viable Brca2\textsuperscript{K0/K0} ES cells are obtained in hypoxanthine-aminopterin-thymidine (HAT) media after CRE-mediated recombination in PL2F7 cells (Fig. 1a)\textsuperscript{6}. However, when PL2F7 cells were transduced with MSCV-CRE (MSCV expressing Cre), Brca2\textsuperscript{K0/K0} HAT-resistant colonies were obtained that had one or two viral integrations (Fig. 1b, Supplementary Fig. 1A).

**BRE overexpression rescues Brca2\textsuperscript{K0/K0} mES cell’s lethality.** To identify the viral insertion sites, we used a splinkerette polymerase chain reaction (PCR)-based method\textsuperscript{30}. One of the viral integrations (in Clone 3d) was at chromosome 5qB1. The integration was within the Mitochondrial Ribosomal Protein L33 (Mrpl33) and upstream of Ribokinase (Rbks) and Brain and Reproductive organ Expressed (Bre) genes (Supplementary Fig. 1B). In addition, within the Rbks locus microRNA 3473e (Mir3473e) is also present that has no human ortholog. To determine the genes that are affected by viral insertion, we performed real-time reverse transcriptase (RT) PCR and compared the expression levels of Mrpl33, Rbks, and Bre in PL2F7 cells and Brca2\textsuperscript{K0/K0};Clone 3d cells. Among these genes, only Bre mRNA showed a significant upregulation (~1.8-fold higher) in Clone 3d cells (Fig. 1c and Supplementary Fig. 1C).

To test whether the overexpression of Bre can account for the viability of Clone 3d, we expressed Hemagglutinin (HA)-tagged BRE cDNA under the control of MSCV LTR in PL2F7 cells (Fig. 1d). CRE was expressed in two independent HA-BRE expressing clones to delete the conditional allele (Fig. 1e, top and middle panels). The HAT-resistant clones were then genotyped to identify the clones that have lost conditional Brca2 allele. We obtained Bre\textsuperscript{2K0/K0} mES cells (referred as Bre\textsuperscript{2K0/K0}; MSCV-CRE) at a frequency of 8–10% (percentage of HAT-resistant recombinant clones) in both the clones tested (Fig. 1e). The clones that do not overexpress BRE failed to generate any viable Bre\textsuperscript{2K0/K0} mES cells after CRE expression (Fig. 1e, lower panel).

We next tested whether BRE overexpression can promote the growth of human BRCA2-deficient cells. We transduced MCF7 cells with (MCF7/BRE) or without (MCF7/Neo) BRE overexpression with lentiviruses expressing two different shRNAs targeting BRCA2 and a non-specific shRNA (Fig. 1f). As predicted, MCF7/Neo cells showed a significantly slower growth in response to BRCA2 knockdown (Fig. 1f). In contrast, BRE overexpression rescued this growth defect in MCF7/BRE cells, which further supports its role in promoting the growth of BRCA2-deficient cells (Fig. 1f).

**Bre overexpressing Brca2\textsuperscript{K0/K0} cells have DNA repair defects.** We examined whether Bre overexpression could compensate for the loss of Brca2 and restore those functions in Brca2\textsuperscript{K0/K0},...
MSCV-BRE ES cells. We tested Brca2KO/KO, MSCV-BRE cells for their ability to form RAD51 foci in response to ionizing radiation (IR) and also examined the integrity of replication forks in response to hydroxyurea (HU). We found that Brca2KO/KO, MSCV-BRE ES cells are defective in both IR-induced RAD51 foci formation (Fig. 2a, b, Supplementary Fig. 2A) as well as protection of stalled replication forks (Fig. 2c). Further, we tested those cells for sensitivity to various genotoxins and found them to be hypersensitive to all DNA-damaging agents tested (Fig. 2d, e and Supplementary Fig. 2B-D). When we examined the metaphase spreads of these cells, we found an increase in chromosomal aberrations (Fig. 2f, g). Taken together, these results suggest that BRE overexpression does not restore the BRCA2-loss-associated defects.

Bre overexpressing cells show radio-resistant DNA synthesis. The embryonic lethality of Brca2-null mice can be partially rescued by targeted deletion of Trp53. We tested whether the Brca2-deficient ES cells rescued by BRE overexpression have intact TRP53 regulation in response to DNA damage. Increased expression of TRP53 in these cells in response to IR suggests that...
BRE-mediated survival of Brca2KO/KO cells is independent of TRP53 (Supplementary Fig. 2E). We then investigated whether the survival of Brca2-deficient mES cells by Bre overexpression is due to a defect in the control of cell cycle progression after DNA damage. We first checked the progression of cells from G1 to S phase after IR by staining the cells with 5-bromo-2'-deoxyuridine (BrdU) and propidium iodide (PI). We found that both the control and Brca2-deficient cells entered S phase after IR, indicating a relaxed G1/S checkpoint in mES cells (Supplementary Fig. 2F-G), consistent with previous reports. We then measured the G2/M checkpoint by staining for the DNA content and phosphorylated histone H3, a mitotic marker. Cells with a functional BRCA2 arrest in the G2 phase immediately after IR even when BRE is over expressed (Supplementary Fig. 2H-I). The cells lacking Brca2 (Brca2KO/KO, MSCV-BRE or Brca2KO/KO, Clone 3d) exhibited a minor defect in G2/M checkpoint (Supplementary Fig. 2H-I). This defect in the G2/M checkpoint is a feature of Brca2-deficient cells.

We analyzed Bre overexpressing cells for intra S-phase checkpoint activation by the radio-resistant DNA synthesis assay. When S-phase cells are exposed to IR, the intra S-phase checkpoint is activated and inhibits DNA synthesis. This inhibition can be measured by 3H-thymidine incorporation. The results indicate that the Brca2KO/KO cells slowed DNA synthesis following DNA damage (Fig. 3a). In contrast, all BRE overexpressing cells (Brca2KO/KO, MSCV-BRE, Brca2KO/KO, Clone 3d or Brca2KO/KO, MSCV-BRE) continued DNA synthesis (Fig. 3a). This suggests that the defect in inhibition of DNA synthesis after IR is not dependent on the absence of functional Brca2, rather dependent on BRE overexpression. After DNA damage, inhibition of DNA synthesis is essential to repair the damage. BRE overexpression impairs this inhibition of DNA synthesis after DNA damage and this impairment might help the BRCA2-deficient cells to continue the cell cycle.

Defects in IR-induced CDC25A degradation by BRE overexpression. The critical event in the inhibition of DNA synthesis following DNA damage is accelerated proteolysis of cell division cycle A (CDC25A) protein, a dual specificity protein phosphatase and one of the most crucial cell cycle regulators. DNA damage-induced degradation of CDC25A protein in turn leads to the inhibition of the cyclin dependent kinase (CDK) activity that facilitates transient blockade of DNA replication. To check the CDC25A level in BRE overexpressing cells, we monitored the protein level following IR in Brca2KO/KO, Brca2KO/KO, MSCV-BRE, Brca2KO/KO, Clone 3d and Brca2KO/KO, MSCV-BRE cells at different time points. The results show that the level of CDC25A protein is comparable among the untreated BRE normal and overexpressing cells (Fig. 3b and Supplementary Fig. 3, lanes 1, 5). Furthermore, a reduction in CDC25A is rapidly induced in control cell line (Brca2KO/KO) in response to IR (Fig. 3b and Supplementary Fig. 3). However, BRE overexpressing cells maintain higher CDC25A levels at all time points after IR compared to the corresponding time points in control cells (Fig. 3b and Supplementary Fig. 3A-B). This indicates that the IR-mediated CDC25A reduction is compromised upon BRE overexpression. Next, we tested how this elevated level of CDC25A in response to IR affects the level of phosphorylated CDK1 (inactive). While the phosphorylated CDK1 levels increased after IR in the control cells, BRE overexpressed cells maintained their CDK1 levels similar to the untreated cells (Fig. 3b). These data confirm that blocking the CDC25A decrease in response to IR can activate its target protein to help these cells to proceed into cell cycle even after DNA damage.

Regulation of CDC25A by BRE in human cancer cell lines. We next tested whether BRE-mediated stabilization of CDC25A levels in response to IR occurs in MCF7 cells. To stably overexpress, we used a loxP-STOP-loxP cassette to induce the expression of the BRE transgene under the control of the chicken actin (CAG) promoter after CRE expression. The levels of CDC25A were not altered upon BRE overexpression in unirradiated MCF7 cells (Fig. 3c, lanes 1, 4; P = 0.21). However, after IR, while CDC25A levels were reduced in parental MCF7 cells (Fig. 3c, lanes 2, 3), cells overexpressing BRE did not show any change in CDC25A level (Fig. 3c, lanes 5, 6). These results suggested that the effect of BRE overexpression on CDC25A stabilization occurred in other cells as well.

To examine the effect of endogenous BRE on CDC25A regulation, we knocked down BRE in MCF7 cells using two different siRNAs and assessed IR-induced CDC25A degradation. As shown in Fig. 3d, a reduction in BRE levels clearly resulted in accelerated degradation of CDC25A (Fig. 3d, compare lane 2-8 with lanes 10-16 and 18-24). We further evaluated the effect of BRE knockdown on CDC25A degradation in other human cancer cell lines. We screened NCI-60 cell panel for BRE and CDC25A expression and selected prostate cancer cell line PC3 and colorectal carcinoma cell line SW620 for higher BRE and CDC25A expression. We also tested a breast cancer cell line ZR75-1 due to its higher level of CDC25A. We found that BRE knockdown caused increased IR-induced CDC25A degradation in all three cell lines (Supplementary Fig. 4, compare lane 3 with lanes 6, 9, and 12 in each panel).

BRE protein stabilization is dependent on MERIT40, a physical interactor of BRE and a component of BRCA1 complex. Therefore, we examined whether the knockdown of MERIT40 had any effect on CDC25A stability in BRE overexpressing cells.
After depletion of MERI40 with siRNA, we failed to get the overexpression of BRE and in those cells, CDC25A undergoes degradation in response to IR (Fig. 3e, lanes 7–12). These data further support a role for BRE in CDC25A stabilization after DNA damage.

**CDC25A is post-translationally stabilized by BRE.** We examined whether BRE transcriptionally regulates CDC25A levels. However, we did not observe any significant changes in CDC25A mRNA levels in cells overexpressing BRE (Supplementary Fig. 5A). To examine if BRE overexpression affected IR-induced...
CDC25A degradation, we analyzed the level of CDC25A protein in the presence of cycloheximide, an inhibitor of protein translation. Interestingly, we found that BRE overexpression enhanced the half-life of CDC25A in response to IR (Supplementary Fig. 5B-C).

Upon exposure to genotoxic stress, CDC25A undergoes ubiquitin-mediated proteolysis. Therefore, we examined whether BRE overexpression affected ubiquitylation of CDC25A after IR. To facilitate the detection of CDC25A, we transiently overexpressed Flag-tagged CDC25A. For equal detection of CDC25A in untreated and irradiated samples, cells were irradiated in the presence of the proteasome inhibitor MG132 and then processed for analysis of CDC25A polyubiquitylation. Although BRE overexpression did not change the ubiquitylation level in unirradiated cells (Fig. 4a, lanes 1, 5), it resulted in significant reduction in the amount of ubiquitylated CDC25A in irradiated cells compared to control cells (Fig. 4a, lanes 2, 6). We further confirmed that the BRE overexpression affects CDC25A K-48 linked poly-ubiquitylation and not K-63 linked (Supplementary Fig. 6).

BRE mediates CDC25A stabilization after DNA damage by USP7. DNA damage induces phosphorylation of CDC25A in a CHK1-dependent manner. Phosphorylated CDC25A is recognized and bound by SCF (Skp, Cullin, F-box) E3-ligase β-TRCP (β-transducin repeat-containing protein) that mediates subsequent ubiquitylation and proteolysis of CDC25A after DNA damage. To determine if BRE overexpression affected CDC25A phosphorylation or CHK1 activation, we compared phosphorylated CDC25A levels and phosphorylated Ser137-CHK1 before and after irradiation. We observed that BRE overexpression neither affected phosphorylation of CDC25A (Supplementary Fig. 7A) nor phosphorylated Ser137-CHK1 (Supplementary Fig. 7B). Furthermore, we found that the level of β-TRCP is not altered upon BRE overexpression and exposure to IR (Supplementary Fig. 7C). We also assessed the level of ubiquitin hydrolase DUB3 that is known to deubiquitylate and stabilize CDC25A. DUB3 levels remained unaltered in mcf7 cells overexpressing BRE compared to parental MCF7 cells, before and after IR (Supplementary Fig. 7C). We also failed to detect any physical interaction between BRE and DUB3 (Supplementary Fig. 7D) or β-TRCP (Supplementary Fig. 7E), indicating that BRE overexpression-mediated CDC25A deregulation is independent of β-TRCP and DUB3.

Next, we searched for other DUBs (deubiquitylating enzymes) that are known to interact with BRE to determine the mechanism by which BRE overexpression reduces CDC25A degradation in response to DNA damage. BRE is a part of the BRISC complex (BRCC36 isopeptidase complex) where it interacts with BRCC36, a DUB that selectively cleaves K63-linked polyubiquitin. K48 polyubiquitin is the major signal for protein degradation, while K63 ubiquitin fulfills other roles such as endocytic trafficking, protein localization after DNA damage response, and activation of the nuclear factor-κB and T-cell receptor pathways in mammalian cells. This suggests that BRCC36 may not play a role in BRE-mediated CDC25A stability. Furthermore, we failed to detect any interaction between BRCC36 and CDC25A making it unlikely to be involved in CDC25A regulation (Supplementary Fig. 7F).

A global proteomic analysis of DUBs and their associated protein complexes identified an interaction between BRE and USP7. USP7 controls the ubiquitylation of many key proteins such as HDM2, FOXO4, PTEF, and Claspin and plays a major role in regulating genome stability and cancer prevention (reviewed in ref. 50). To investigate if BRE and USP7 interaction plays a role in the stabilization of CDC25A after IR, we knocked down USP7 in BRE overexpressing and control MCF7 cells using two different siRNAs (Fig. 4b). USP7 knockdown did not change CDC25A levels in unirradiated cells either in presence or absence of overexpressed BRE (Fig. 4b, lanes 1, 3, 5, and 7, 9, 11). In BRE overexpressing cells, USP7 knockdown resulted in IR-induced CDC25A degradation indicating that USP7 plays a key role in the stabilization of CDC25A after DNA damage in those cells (Fig. 4b, lanes 7–12). In contrast to CDC25A, the levels of HDM2, a known USP7 substrate, were reduced independent of IR or BRE overexpression (Fig. 4b).

We also evaluated the effect of USP7 inhibitor PS901 on IR-induced CDC25A degradation (Supplementary Fig. 8). In the absence of BRE overexpression, CDC25A was degraded in response to IR independent of the inhibitor treatment (Supplementary Fig. 8, lanes 1–4). However, in BRE overexpressing cells, while CDC25A did not undergo degradation after irradiation, its levels were reduced in the presence of USP7 inhibitor (Supplementary Fig. 8, lanes 5–8). This further confirms the involvement of USP7 in BRE-mediated suppression of IR-induced CDC25A degradation.

Next, we examined CDC25A polyubiquitylation in the presence and absence of BRE upregulation after USP7 knockdown. To detect polyubiquitylation, we treated the cells with MG132 after IR. We observed that USP7 knockdown in BRE overexpressing cells resulted in an increase in the level of polyubiquitylated CDC25A after IR (Supplementary Fig. 9A, lanes 9, 10, 13, 14) when compared to controls (Supplementary Fig. 9A, lanes 5 and 6). These data support that BRE upregulation facilitates deubiquitylation of CDC25A in the presence of DNA damage by USP7. We next evaluated the effect of overexpression of USP7 and a catalytic inactive USP7 on CDC25A polyubiquitylation (Fig. 4c). Similar to BRE, overexpression of USP7 reduces IR-induced polyubiquitylation of CDC25A (Fig. 4c, lanes 4 and 5) whereas, polyubiquitylated CDC25A is observed after IR when catalytic inactive USP7 is expressed (Fig. 4c, lanes 6 and 7). However, restoration of polyubiquitylated CDC25A levels is incomplete, possibly due to the presence of endogenous USP7. Taken together, these results further support a role for USP7 in CDC25A regulation.

BRE, USP7, and CDC25A complex formation upon DNA damage. To examine whether USP7 regulates CDC25A via direct physical interaction or by some other mediator protein, we performed immunoprecipitation using different antibodies (Fig. 4d).

**Fig. 2** BRE overexpression rescues Brca2KO/KO cell viability without affecting BRCA2 function. a Ionizing radiation (IR)-induced RAD51 foci formation in Brca2KO/KO and Brca2Cko/KO: MSCV-BRE ES cells. RAD51 foci are in turquoise, γ-H2AX foci in magenta, and nuclei are stained with 4,6-diamidino-2-phenylindole (DAPI, blue). Merged images show co-localization of RAD51 and γ-H2AX foci (yellow foci). b Quantification of RAD51 foci shown in a. Twenty-five nuclei were counted for each genotype. Error bars represent the mean ± s.d. c Scatter plot showing DNA fiber analysis of the indicated cell lines. P values were calculated using Mann–Whitney test. d Methylene blue-stained plates showing the sensitivity of Brca2KO/KO and Brca2Cko/KO: MSCV-BRE ES cells to different doses of IR. e Quantification of the colonies shown in d. Colony numbers obtained in plates with no treatment (0 Gy) are considered as 100%. Average of three experiments is shown. Error bars represent s.d. values. f Representative metaphase spread showing chromosomal aberration (marked with arrows) in Brca2KO/KO and Brca2Cko/KO: MSCV-BRE ES cells. g Quantification of different aberrations as well as total aberrations in 50 randomly selected Brca2KO/KO and Brca2Cko/KO: MSCV-BRE metaphase spreads.
and Supplementary Fig. 9B–C). Immunoprecipitation with BRE antibody pulled down CDC25A independent of IR, but in this complex, endogenous USP7 was detected only after IR (Fig. 4d). BRE overexpression resulted in an increase in the amount of immunoprecipitated CDC25A and USP7, indicating that BRE overexpression facilitates increased interaction between BRE-CDC25A-USP7 in response to IR (Fig. 4d). Immunoprecipitation using USP7 antibodies further confirmed that this interaction is induced only after DNA damage (Supplementary Fig. 9B). Finally, we confirmed the interaction between BRE, CDC25A, and USP7 by pulling down Flag-tagged CDC25A in irradiated cells that also overexpresses BRE (Supplementary Fig. 9C). In Flag-tagged CDC25A immunoprecipitation complexes, we failed to detect endogenous USP7 in irradiated control cells (Supplementary Fig. 9C). This is likely due to our inability to detect very low levels of endogenous USP7 by western blotting. Further, we tested whether the interaction between USP7 and CDC25A is dependent on BRE. We knocked down BRE in MCF7 cells and failed to detect USP7/CDC25A interaction, indicating that USP7 interaction with CDC25A depends on BRE (Supplementary Fig. 9D). We also evaluated if some of the known BRE interactors are present in BRE/CDC25A complex. We failed to co-
immunoprecipitate BRCC36, BRCA1, or RAP80 with CDC25A, whereas MERIT40 was found to interact with CDC25A (Supplementary Fig. 9E and F). Overall, our immunoprecipitation results clearly demonstrate the formation of a novel multiprotein complex consisting of at least BRE, CDC25A, USP7, and MERIT40 in response to DNA damage. The levels of this DNA damage-induced protein complex are increased in cells overexpressing BRE (Fig. 4e).

BRE contains three (+12 to +15 [PMLS]; +94 to +97 [PDPS]; and +201 to +204 [ALLS]) putative USP7-binding sequences (P/AxxS) that were previously identified in other USP7 interacting proteins53. We further tested if these sequences are important for binding to USP7 after irradiation. We generated different deletion mutants of BRE tagged with HA on their C-terminus (Fig. 4f upper panel). Immunoprecipitation with USP7 antibody pulled down all different deletion mutants of BRE except the one lacking all three USP7-binding sequences (FLΔ123, Fig. 4f). Next, we examined the region of USP7 responsible for binding to BRE. We generated two deletion mutants of USP7, either containing N-terminal TRAF (tumor necrosis factor (TNF) receptor-associated factor) domain or C-terminal region without TRAF domain (Supplementary Fig. 9G)55. Immunoprecipitation with BRE antibody shows that the interaction is mediated via N-terminal TRAF domain (Supplementary Fig. 9G).

We then tested if the disruption of the interaction between BRE and USP7 affects the known function of BRE in the stability of RAPP80 or BRCC36 proteins56. We knocked down BRE in NIH3T3 cells and expressed either HA-BRE or HA-FLΔ123 BRE protein (human BRE cDNA) and examined RAPP80 and BRCC36 protein levels (Supplementary Fig. 10). Expression of HA-BRE or HA-FLΔ123 BRE restores RAPP80 and BRCC36 protein level after mouse BRE knockdown, indicating that HA-FLΔ123 BRE does not affect the key function of BRE (Supplementary Fig. 10).

We also examined the effect of BRE FLΔ123 in MCF7 cells on CDC25A levels in response to IR. While BRE overexpression suppressed IR-induced CDC25A degradation, overexpression of BRE FLΔ123 failed to do that (Fig. 4g). This provides a strong evidence that BRE overexpression prevents IR-induced CDC25A degradation and its interaction with USP7 is essential for this.

Survival of Brca2ΔKO/KO mES cells by CDC25A overexpression.

Next, we overexpressed BRE defective in binding to USP7 (FLΔ123) in PL2F7 mES cells and selected the stable clones expressing the mutated BRE. We then examined its effect on IR-induced CDC25A stabilization. Similar to MCF7 cells, overexpression of BRE FLΔ123 failed to stabilize CDC25A in mES cells after irradiation (Fig. 5a). Further, we tested the ability of the mutant BRE to rescue the lethality of Brca2ΔKO/KO cells. After deletion of conditional Brca2 allele in those cells by CRE expression, we failed to obtain any viable Brca2ΔKO/KO cells (0/345 colonies screened) (Fig. 5b, upper panel). As control, when conditional Brca2 allele was deleted from BRE overexpressed cells, we obtained several Brca2ΔKO/KO cells (14/276 colonies screened) (Fig. 5b, lower panel). These data support that the survival of Brca2ΔKO/KO cells after BRE overexpression is due to its effect on CDC25A stabilization.

Next, we asked whether higher levels of CDC25A could rescue the lethality of Brca2ΔKO/KO cells. To directly test this, we expressed Flag epitope tagged Cdc25A cDNA from MSCV LTR in PL2F7 mES cells (Fig. 5c). We selected two independent clones in which, after IR, the level of CDC25A remained higher compared to irradiated control cells (Fig. 5c, lanes 4, 6). Further, when we deleted the conditional Brca2 allele in those cells by CRE expression, we obtained viable Brca2ΔKO/KO cells (Fig. 5d). These CDC25A overexpressing Brca2ΔKO/KO cells (Brca2Δko/KO;MSCV-Cdc25A) showed defects in IR-induced RAD51 foci formation, increased chromosomal instability, and increased sensitivity to DNA-damaging agents indicating the impairment of Brca2 DSB repair function (Supplementary Fig. 11). Taken together, these data further support that BRE overexpression supports the viability of Brca2ΔKO/KO cells by suppressing DNA damage-induced CDC25A degradation.

The effect of BRE on cell viability is independent of the DSB repair function of BRCA2. Therefore, we hypothesized that BRE overexpression should be able to rescue the cell lethality associated with loss of other DNA repair genes like Brca1, as well. To test this, we overexpressed HA tagged BRE from MSCV LTR into previously described37 PL2F8 Brca1 conditional mES cells (Brca1ΔCKO/KO) (Supplementary Fig. 12A). Upon deletion of the conditional Brca1 allele, we obtained Brca1ΔKO/KO clones in Brca1 conditional mES cells (Brca1ΔKO/KO;MSCV-BRE) but none in the parental PL2F8 (Brca1ΔCKO/KO) cells (Supplementary Fig. 12B). This further supports that BRE overexpression affects general cellular machinery rather than compensate for the loss of a specific function of BRCA2.

Further, we analyzed publicly available data sets for CDC25A expression in BRCA1/2 mutant tumors. We observed higher CDC25A mRNA expression in tumors carrying mutations in BRCA1/2 genes in multiple data sets (Fig. 5e, Supplementary Table 1). We next examined the correlation between BRE and CDC25A levels in BRCA2 mutant human breast tumors. We evaluated the expression of BRE in 15 breast tumors by immunohistochemistry. We found that 9/15 (60%) tumors from BRCA2 mutation carriers had higher BRE expression while six tumors showed relatively low levels (Fig. 6a). Interestingly, of the nine BRE high tumors, eight showed higher CDC25A expression.

**Fig. 3 BRE overexpression affects IR-induced CDC25A degradation.** a DNA synthesis in ES cells after different doses of IR. b Western blot analysis of CDC25A and Tyr15 phosphorylation of CDK1 (p-CDK1) at different times after exposing the cells to 6 Gy IR in Brca2ΔKO/KO;MSCV-BRE cells compared to Brca2ΔKO/KO cells. GAPDH was used as a loading control. Numbers below indicate the lane numbers. The quantification of CDC25A (middle panel) and p-CDK1 (lower panel) band intensities for each cell line is shown as histogram. Relative band intensities were calculated by dividing GAPDH-normalized CDC25A/p-CDK1 intensity at particular time point with GAPDH-normalized CDC25A/p-CDK1 intensity of corresponding untreated cells. c MCF7 cells with inducible HA-BRE expression cassette were transduced with CRE plasmid and subjected to 6 Gy IR after 48 h of transfection. Western blots of endogenous CDC25A in presence (lanes 4–6) and absence (lanes 1–3) of HA-BRE expression at different times after irradiation is shown in the upper panel. Lower panel shows the quantification of CDC25A band intensity normalized against GAPDH. d Immunoblot showing CDC25A degradation after IR treatment in MCF7 cells transfected either with non-specific (NS) siRNA or two different siRNAs against BRE (#1 and #2). Histone H3 was used as a loading control. Relative CDC25A band intensities were calculated by dividing GAPDH-normalized CDC25A intensity at a particular time point with GAPDH-normalized CDC25A intensity of untreated (0 h IR) cells of corresponding siRNA treatment. e Western blot showing IR-induced CDC25A degradation in MCF7 cells with stably integrated CRE inducible HA-BRE expression cassette after transfection either with non-specific (NS) siRNA or two different siRNAs against MERIT40 (#1 and #2) along with CRE-expressing plasmid. Non-specific (NS) siRNA transfection was used as control. Relative abundance of CDC25A at a particular time point was measured by comparing GAPDH-normalized band intensities at that point divided by GAPDH-normalized CDC25A intensity of untreated (0 h IR) cells of corresponding treatment. All histograms show the average of three independent experiments and error bars represent s.d. P values were calculated using paired two-tailed t-test and tabulated in Supplementary Table 2

This further supports that BRE overexpression affects general cellular machinery rather than compensate for the loss of a specific function of BRCA2.

Further, we analyzed publicly available data sets for CDC25A expression in BRCA1/2 mutant tumors. We observed higher CDC25A mRNA expression in tumors carrying mutations in BRCA1/2 genes in multiple data sets (Fig. 5e, Supplementary Table 1). We next examined the correlation between BRE and CDC25A levels in BRCA2 mutant human breast tumors. We evaluated the expression of BRE in 15 breast tumors by immunohistochemistry. We found that 9/15 (60%) tumors from BRCA2 mutation carriers had higher BRE expression while six tumors showed relatively low levels (Fig. 6a). Interestingly, of the nine BRE high tumors, eight showed higher CDC25A expression.
These results suggest a correlation between high CDC25A expression and higher BRE expression in BRCA-deficient breast tumors.

**BRE overexpression supports growth of BRCA2-deficient cells.**

BRE overexpression is known to promote the growth of liver tumors.58 Besides, high BRE expression correlates with poor prognosis in non-radiotherapy treated breast cancer patients.59 We therefore examined the effect of overexpression of BRE on the growth of Brca2-deficient cells in mice. We stably expressed HAtagged BRE in KB2P1.21 mouse mammary tumor cells derived from K14-Cre;Brca2F11/F11; p53F2-10/F2-10 and then injected the cells into athymic nude mice and monitored tumor growth. Brca2-deficient BRE overexpressing cells (KB2P1.21 + BRE) showed accelerated tumor growth relative to cells without BRE.
overexpression (Fig. 6b). We examined the level of BRE and CDC25A in these tumors and found that higher level of expression was maintained in tumors derived from BRE overexpressing cells (Fig. 6c, top panel). Also, the tumors that showed higher BRE expression exhibited high CDC25A expression (Fig. 6c middle panel). These results demonstrate that BRE overexpression promotes the growth of Brca2-deficient cells in vivo by regulating CDC25A.

Discussion

The mechanism underlying the development of cancer due to loss of BRCA1 and BRCA2 has been explained by the ‘caretaker and gatekeeper’ hypothesis. According to this hypothesis, BRCA proteins are considered to be ‘caretakers’ and loss of ‘gatekeeper’ function is essentially detrimental to cells. In response to loss of BRCA1/2, cells activate checkpoint mechanisms to prevent cell cycle progression and induce apoptosis in the presence of unrepaird DNA damage. Thus, the survival of BRCA-deficient cells either requires its cellular function complementation or loss of other genetic factors or the loss of a ‘gatekeeper’ function that can bypass the activated checkpoint mechanisms. The combination of those two events together can contribute to the development of cancer. One such combination is the loss of TRP53 along with the bypass the activated checkpoint mechanisms. The combination of BRCA1 and BRCA2 has been explained by the unknown, we propose that the presence of high CDC25A in the absence of BRCA2 can promote mitotic entry of such cells. This can exert mitotic catastrophe. It is possible that some cells may accumulate secondary mutations due to their unstable genome and these mutations can then support cell viability. This is supported by the low number of rescued Brca2KO/KO cells obtained by BRE or CDC25A overexpression. Similarly, when we examined the effect of BRE overexpression on the growth of MCF7 cells after BRCA2 knockdown, cell proliferation was found to be comparable to the wild-type cells at initial time points (Fig. 1f, days 1–5). At later time points (Fig. 1f, after day 5), the cell proliferation was significantly reduced compared to the wild-type cells. This suggests that although BRE overexpression contributes to resistance to BRCA2-loss-induced growth arrest, not all cells survive or proliferate to the same extent.

In conclusion, we identified a novel mechanism of survival of BRCA2-deficient cells by CDC25A, which is frequently upregulated in tumors from BRCA1/2 mutation carriers. Furthermore, we have also uncovered a novel multiprotein complex containing BRE-USP7-CDC25A that has revealed a new mechanism of CDC25A regulation. Considering that CDC25A can act as a biomarker for ATR inhibitor sensitivity and the increased expression of CDC25A in BRCA1/2 tumors (Fig. 5e), it will be intriguing to test such tumors for their sensitivity to ATR inhibitors. Also, combining ATR inhibitors with PARP inhibitors can be efficacious for treating BRCA1/2 tumors.

Fig. 4 DNA damage-induced BRE-USP7 interaction stabilizes CDC25A. a Ubiquitylation of FLAG-CDC25A in cells harvested 4 h after 6 Gy IR in absence (lanes 1–4) or presence (lanes 5, 6) of exogenous BRE. CDC25A was immuno-precipitated using anti-FLAG antibody (lanes 1, 2, 5, 6), IgG was used as control (lanes 3, 4). b MCF7 cells stably expressing CRE-inducible HA-BRE were transfected with either non-specific (NS, lanes 1–2 and 7–8) or two independent USP7-specific (USP7 #1, lanes 3, 4, 9, 10 and USP7 #2, lanes 5, 6, 11, 12) siRNAs along with or without plasmids expressing CRE and irradiated with 6 Gy IR. Western blot shows the abundance of endogenous CDC25A in non-IR cells and 4 h after irradiation. HDM2 was used as a control for USP7 knockdown. c FLAG-CDC25A ubiquitylation in cells harvested 4 h after 6 Gy IR in absence (lanes 1–3) or in presence of exogenous USP7 (lanes 4, 5) or catalytic inactive USP7 (USP7-CA; lanes 6, 7). Anti-FLAG antibody (lanes 2–7) was used to pull down CDC25A, IgG was used as control (lane 1). HDM2 was used as a control for USP7 activity. d Co-immunoprecipitation of FLAG-CDC25A, BRE, and endogenous USP7 from MCF7 cells using anti-BRE antibody (lanes 1–4) and IgG antibody (lanes 5–6); 5 μM MG132 was added after irradiation to increase CDC25A level and harvested after 2 h. e Model depicting the interaction of BRE, CDC25A, and USP7. In presence of DNA breaks, BRE interacts with USP7 and then BRE, USP7, and CDC25A complex is formed. For simplicity, MERIT40 is not included in the model. f Co-immunoprecipitation of USP7 and different deletion mutants of BRE tagged with HA-epitope from irradiated HEK293 cells using USP7 antibody. Top panel shows the schematic representation of different deletion mutants of BRE. Numbers in the top panel mark different USP7 binding motifs. Stars indicate different HA-BRE proteins. g Western blots showing IR-induced degradation of CDC25A after expressing HA-BRE or HA-BRE mutant defective in USP7 binding (FLΔ123). GAPDH was used as a loading control for all blots. Histogram represents mean ± s.d. values of relative band intensities. P values are calculated using the paired two-tailed t-test and presented in Supplementary Table 2.
Methods

Plasmids, antibodies, and reagents. MSCV-Cre plasmid was a kind gift from Dr. Dan Littman. HA epitope was tagged to the C-terminus of human BRE cDNA and was cloned in to MSCVneo vector (Clontech #634401). To generate MSCV-Cdc25a expression vector, mouse Cdc25A cDNA was N-terminally fused with FLAG epitope and cloned into MSCVneo vector (Clontech). For inducible expression of BRE, HA-tagged human BRE cDNA was cloned into vector pCCALL2-IRES-GFP. The pCDNA3.1+ (Invitrogen) vector was used for transient expression of FLAG-Cdc25A, HA-BRE, and FLAG-DUB3. For the expression of BRCC36, Ubiqutin, USP7, catalytically inactive USP7, β-TRCP3, RAP80, MERIT40, and BRCA1 pOZ-N-FH BRCC36 (Addgene #27496) FLAG-HA-BRCC3 (Addgene #22540), HA-UBiquitin (Addgene #18712), pQHA-USP7 WT puroR (Addgene #46753), pCI-neo-FLAG-HAUSP (Addgene #16655), pQHA-USP7 CS puroR (Addgene #46754), pTRCP3-Myc (Addgene #25902), pOZ-N-FH RAP80 (Addgene #27501),

Fig. 5 CDC25A overexpression can rescue ES cell lethality of Brca2KO/KO. a Immunoblot showing IR-induced degradation of CDC25A in PL2F7 mES cells expressing either HA-BRE or HA-BRE mutant defective in USP7 binding (FLΔ123). GAPDH was used as control. The histogram below shows the average relative abundance of CDC25A at particular time points from three independent experiments. All intensities were normalized against corresponding GAPDH band intensities. Supplementary Table 2 shows the P values. b Representative Southern blot analysis showing the identification of Brca2KO/KO cells (marked with solid stars) after CRE-mediated deletion of conditional allele in indicated cell lines. Upper band: conditional allele (CKO); lower band: knock-out allele (KO). c Western blot showing CDC25A abundance in Brca2KO/KO and Brca2KO/KO; MSCV-Cdc25a ES cells before (lanes 1, 3, 5) and 2 h after 6 Gy IR (lanes 2, 4, 6). Top panel represents the scheme of expression of FLAG-CDC25A from MSCV LTR. GAPDH was used as a loading control. d Southern blot analysis of HAT-resistant ES cell colonies after CRE-mediated deletion of conditional allele in Brca2CKO/KO; MSCV-Cdc25a ES cells to identify Brca2KO/KO clones (marked with solid stars), upper band: conditional allele (CKO); lower band: knock-out allele (KO). e CDC25A mRNA expression in two different breast cancer data sets from The Cancer Genome Atlas (TCGA). Left panel represents the data set of METABRIC breast cancer with 2433 tumors and right panel shows the breast invasive carcinoma data set of 825 tumors. Dots or squares in graphs represent individual tumors. Middle line, median; whiskers, minimal and maximum values. Significance was calculated using unpaired t-test with Welch's corrections
pOZ-N-FH MERIT40 (Addgene # 27498) and pBABEpuro HA Brca1 (Addgene #14999) were used, respectively. The antibodies used for co-immunoprecipitation, immunofluorescence, and western blots were anti-BRE (C-16: sc-48847 and sc-376453; Santa Cruz Biotech, 1:500 dilution for western blots), anti-BRCC36 (ab62075; Abcam and sc131122; Santa Cruz Biotech, 1:1000 dilution for western blots), anti-CDC25A (F-6: sc-7389; Santa Cruz Biotech, 1:200 dilution), anti-FLAG (F7425 and F3165; Sigma-Aldrich, 1:2000 dilution for western blot), anti-HA (12013819001; Roche, 1:2000 dilution), anti-USP7 (H-200: sc-30164 and H12: sc-137908; Santa Cruz Biotech and ab4080; Abcam, 1:1000 dilution for western blot), anti-β TRCP (ab118006; Abcam, 1:500 dilution), anti-DUB3 (ab174914; Abcam and H00377630-M01; Abnova, 1:1000 dilution for western blot), anti-RAP80 (A300-764A-M; Bethyl laboratories, 1:500 dilution for western blot), K-48 linkage

Viable cell with damaged DNA

High BRE
Loss of BRCA2

Accumulation of DNA damage

Proteasomal degradation

Cell cycle arrest and apoptosis

Normal BRE
Loss of BRCA2
specific antibody (#42895; Cell Signaling, 1:500 dilution), K-63 linkage specific antibody (#56215; Cell Signaling, 1:500 dilution), anti-histone H3 (#9715; Cell Signaling, 1:500 dilution), anti-HDM2 (sc-65154; Santa Cruz Biotech, 1:500 dilution), anti-GAPDH (21188; Cell Signaling, 1:4000 dilution), anti-ACTIN (C2: sc-8432; Santa Cruz Biotech, 1:40,000 dilution), anti-phosphorylated CHK1 (12502; Cell Signaling, 1:500 dilution), anti-phosphorylated CDK1 (#9111; Cell Signaling, 1:1000 dilution), anti-p-p53 (#2524; Cell Signaling, 1:5000 dilution), anti-RAD51 (sc-56; Santa Cruz Biotech, 1:2000 for western blots, 1:100 for foci assay), anti-α-tubulin (Mab 25D1, Sigma, 1:2000 dilution), secondary antibody and AlexaFluo594-conjugated anti-rat IgG secondary antibody and AlexaFluoro594-conjugated anti-rat IgG secondary antibody for 1 h at room temperature. After rinsing with PBS, the slides were mounted by mounting media (Molecular Probe, Invitrogen). The images were captured in Zeiss Axiol Imager Z1 microscope and the fiber length was measured by ImageJ software (NIH).

**Growth analysis of MCF7 cells.** A total of 200,000 cells were seeded in triplicate for each cell line in a 6-cm dish. At indicated time points, cells were trypsinized, harvested by Beckman Coulter cell harvester. (from http://www.beckman.com). Cells were counted by dividing the cell number at a particular time point by the cell number after 24 h of seeding. Each plate was counted twice and the average was taken. For each time point, an average of three independent plates was plotted.

**DNA fiber assay.** After pulsing sequentially by 8 μg/ml CdU for 15 min followed by 90 μg/ml IdU for 15 min, the cells were treated with 4 μM HU for 3 h and were resuspended in PBS. Approximately 3 x 10^5 cells in 3 μl volume were mixed with 7 μl lysis buffer (200 μM Tris-HCl (pH 7.4), 50 μM EDTA, 0.5% SDS) on glass slides and incubated at room temperature for 8 min before DNA fiber was spread. Fibers were then fixed in methanol and acetic acid (3:1) at 4 °C overnight, rehydrated by PBS followed by denaturation in 2.5 M HCl for 1 h. After rinsing with PBS, slides were fixed with 4% paraformaldehyde for 10 min. Slides were washed with PBS, rehydrated by PBS followed by denaturation in 2.5 M HCl for 1 h and incubated with anti-BrDU antibody (mouse, #347580, Becton Dickinson, 1:100 dilution) and anti-BrDU antibody (rat, ab5632, Abcam, 1:500 dilution) at 4 °C overnight. Next day, slides were rinsed with PBS with 0.1% Triton X-100, treated with AlexaFluor594-conjugated secondary antibody (Thermo Fisher), and AlexaFluor488-conjugated secondary antibody for 1 h at room temperature. After rinsing with PBS, the slides were mounted by mounting media (Molecular Probe, Invitrogen). The images were captured in Zeiss Axiol Imager Z1 microscope and the fiber length was measured by ImageJ software (NIH).
with anti-BRE antibody (GTX09991; Genetex, 1:200 dilution) or with anti-
CDC25A antibody (sc-97; Santa Cruz Biotech, 1:400 dilution). For control, one
slide was stained with normal IgG (Santa Cruz Biotech). The signal was detected by
Elite ABC HRP detection kit (Vectorstain). Microscopic observation was performed
using the Axiosplan2 upright microscope (Zeiss). Intensities of staining were
measured using Image J software. Staining intensities with values >0.45 (arbitrary
unit) were considered as high expression and lower than 0.45 were considered as
low expression.

**Allograft assay.** Mouse tumor cell lines were harvested, counted, and diluted to a
concentration of 2 x 10⁶ cells/200 μl of L15 medium and injected sub-cutaneously
into the flanks of 6-week-old nude mice. Six mice were used in each group. No
selection criteria was used for selecting the mice for each group. Tumor growth was
measured twice on every week blindly. Tumor volume (in mm³) was calculated as a
product of 2 x length x width. Mice were maintained according to the procedures
outlined in the Guide for the Care and Use of Laboratory Animals, under an
approved Animal Care and Use Committee (ACUC) protocol.

**Statistics.** All data are expressed as means ± s.d., if not indicated. Statistics were
performed using data from three independent experiments. For relative quantifi-
cation of protein band intensity, loading control normalized intensity at a parti-
ticular time point was divided by loading control normalized intensity of
corresponding untreated cells. Differences between two groups were compared
using a two-tailed Student’s t-test (Prism). The data are normally distributed and P
< 0.05 was considered statistically significant. For the allograft experiment, the
difference between the two groups (BRE overexpressed vs. non-overexpressed) was
measured by analysis of variance ANCOVA using Prism software. No statistical
methods or criteria were used to estimate sample size or to include or exclude
samples. All group allocations during the experiments were blinded by the inves-
tigators unless otherwise specified.

Additional methods are described in the Supplementary Methods section.

**Data availability.** Uncropped blots are presented in Supplementary Fig. 13. All
relevant data are available from the authors on request.

Received: 23 May 2017 Accepted: 12 January 2018
Published online: 07 February 2018

**References**

1. Breast Cancer Linkage C. Cancer risks in BRCA2 mutation carriers. J. Natl
Cancer Inst. 91, 1310–1316 (1999).
2. Wooster, R. et al. Identification of the breast cancer susceptibility gene
BRCA2. Nature 378, 789–792 (1995).
3. Wang, Y. et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk
of lung cancer. J. Med. Genet. 1310–1316 (1999).
4. Murphy, K. M. et al. Evaluation of candidate genes MAP2K4, MADH4,
8. Stark, J. M., Pierce, A. J., Oh, J., Pastink, A. & Jasin, M. Genetic steps of
9. Lomonosov, M., Anand, S., Sangrithi, M., Davies, R. & Venkitaraman, A. R.
10. Venkitaraman, A. R. Cancer suppression by the chromosome custodians,
14. Jonkers, J. et al. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
15. Crook, T. et al. p53 mutation with frequent novel condons but not a mutator
phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 17,
1644 (1998).
16. Greenblatt, M. S., Chappuis, P. O., Bond, J. P., Hamel, N. & Foulkes, W. D.
TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line
mutations: distinctive spectrum and structural distribution. Cancer Res. 61,
4092–4097 (2001).
17. Ding, X. et al. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
Nat. Commun. 7, 12456 (2016).
18. Ding X. et al. Survival of BRCA2-deficient cells is promoted by GIPC3, a novel
genetic interactor of BRCA2. Genetics 207, 1335–1345 (2017).
19. Rebeck, T. R. et al. Modification of BRCA1-associated breast and ovarian
cancer risk by BRCA1-interacting genes. Cancer Res. 71, 5792–5805 (2011).
20. Chan, M. Y. et al. BRE is an antipotic protein in vivo and overexpressed in
human hepatocellular carcinoma. Oncogene 27, 1208–1217 (2008).
21. Cooper, E. M. et al. K5–specific deubiquitination by two JAMM/MPN+ complexes:
BRISC-associated Brcc36 and proteasomal Poh1. EMBO J. 28, 621–631 (2009).
22. Dong, Y. et al. Regulation of BRCC, a holoenzyme complex containing
BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair.
Mol. Cell. 12, 1087–1099 (2003).
23. Feng, L., Huang, J. & Chen, J. MERIT40 facilitates BRCA1 localization and
daDNA damage repair. Genes Dev. 23, 719–728 (2009).
24. Sobhian, B. et al. RAP80 targets BRCA1 to specific ubiquitin structures at
DNA damage sites. Science 326, 1199–1202 (2009).
25. Shao, G. et al. MERIT40 controls BRCA1–Rap80 complex integrity and
recruitment to DNA double-strand breaks. Genes Dev. 23, 740–754 (2009).
26. Li, Q. et al. A death receptor-associated anti-apoptotic protein, BRE, inhibits
mitochondrial apoptotic pathway. J. Biol. Chem. 279, 52106–52116 (2004).
27. Gu, C., Castellino, A., Chan, J. T. & Chao, M. V. BRE: a modulator of TGF-
alpha action. FASEB J. 12, 1101–1108 (1998).
28. Shi, W. et al. BRE plays an essential role in preventing replicative and DNA
damage-induced premature senescence. Sci. Rep. 6, 23506 (2016).
29. Grez, M., Akgun, E., Hilberg, F. & Ostertag, W. Embryonic stem cell virus, a
recombiant murine retrovirus with expression in embryonic stem cells. Proc.
Natl Acad. Sci. USA. 87, 9202–9206 (1990).
30. Devon, R. S., Porteous, D. J. & Brookes, A. J. Splinkterettes—improved
vectorettes for greater efficiency in PCR walking. Nucleic Acids Res. 23,
1644–1645 (1995).
31. Holloman, W. K. Unraveling the mechanism of BRCA2 in homologous
recombination. Nat. Struct. Mol. Biol. 18, 748–754 (2011).
32. Schlacher, K. et al. Double-strand break repair-independent role for BRCA2 in
blocking stalled replication fork degradation by MRE11. Cell 145, 529–542
(2011).
33. Hong, Y. & Stambrook, P. J. Restoration of an absent G1 arrest and protection
from apoptosis in embryonic stem cells after ionizing radiation. Proc. Natl
Acad. Sci. USA. 101, 14443–14448 (2004).
34. Alamdari, M. et al. ES cells do not activate p53-dependent stress responses
and undergo p53-independent apoptosis in response to DNA damage. Curr.
Biol. 14, 145–148 (2005).
35. Kuznetsova, S. G., Liu, P. & Sharan, S. K. Mouse embryonic stem cell-based
functional assay to evaluate mutations in BRCA2. Nat. Med. 14, 875–881
(2008).
36. Davies, A. A. et al. Role of BRCA2 in control of the RAD51 recombination and
daDNA repair protein. Mol. Cell. 7, 273–282 (2001).
37. Stark, J. M., Pierce, A. J., Oh, J., Fastnik, A. & Jasim, M. Genetic steps of
mammalian homologous repair with distinct mutagenic consequences. Mol.
Cell. Biol. 24, 9305–9316 (2004).
38. Lomanovov, M., Anand, S., Sangrithi, M., Davies, R. & Venkitaraman, A. R.
Stabilization of stalled DNA replication forks by the BRCA2 breast cancer
susceptibility protein. Genes Dev. 17, 3017–3032 (2003).
39. Venkitaraman, A. R. Cancer suppression by the chromosome custodians,
BRCA1 and BRCA2. Science 343, 1470–1475 (2014).
40. Lee, H. et al. Mitotic checkpoint inactivation fosters transformation in cells
lacking the breast cancer susceptibility gene, Brca2. Mol. Cell. 4, 1–10 (1999).
41. Patel, K. J. et al. Involvement of Brca2 in DNA repair. Mol. Cell. 1, 347–357
(1998).
42. Ludwig, T., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. Targeted
mutations of breast cancer susceptibility gene homologs in mice: lethal
phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53
nullizygous embryos. Genes Dev. 11, 1226–1241 (1997).
43. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a
conditional mouse model for breast cancer. Nat. Genet. 29, 418–423 (2001).

**ARTICLE**

| DOI: 10.1038/s41467-018-03020-6 | www.nature.com/naturecommunications | 14 | NATURE COMMUNICATIONS | 2018:9:537 |
64. Novak, A., Guo, C., Yang, W., Nagy, A. & Lobe, C. G. Z/E2, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. *Genesis* **28**, 147–155 (2000).

65. Ray, D. et al. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. *Nature* **260**, 886–890 (2010).

66. Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. *Nat. Commun.* **7**, 11479 (2016).

67. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature* **490**, 61–70 (2012).

Acknowledgements
We thank our members of laboratory for helpful discussions and suggestions. We thank Dr. Michael Kuehn for help with MSCV transduction in ES cells and Drs. Jairaj Acharya, Ira Daar, Debananda Pati, Xia Ding, Suzanne Hartford, and Andre Nussenzweig for their comments and critical review of the manuscript. We thank Dr. Dan Littman (New York University School of Medicine) for MSCV-Cre construct, Dr. Corinne Lobe (Sunnybrook Health Science Center, Toronto, Ontario, Canada) for PCALL2-ires-GFP plasmid, Drs. Jos Jonkers and Peter Bounmwan (Netherland Cancer Institute) for mammary tumor cell lines. We thank Dr. Sudhirkumar Yanapelawar for help with immunohistochemistry and Dr. Erkan Kiris for help with in vivo ubiquititation assays. We also thank Allen Kane (SAIC-Frederick, Inc., Scientific Publications, Graphics & Media Department) for help with the illustrations. This research was sponsored by the Intramural Research Program, Center for Cancer Research, National Cancer Institute, US National Institutes of Health.

Author contributions
K.B. designed and performed the experiments, analyzed the data, and wrote the paper. S.P., A.Y., V.S., A.B. and S.C. designed and performed the experiments, analyzed the data. B.K.M., S.B. and S.L.N. provided technical help. S.K.S. conceived the study, analyzed the data, and wrote the paper.

Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-018-03020-6.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.